AUTHOR=Liu Renli , Liu Liping , Wei Chaojie , Li Dong 

TITLE=IL-33/ST2 immunobiology in coronary artery disease: A systematic review and meta-analysis

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=9

YEAR=2022

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.990007

DOI=10.3389/fcvm.2022.990007

ISSN=2297-055X

ABSTRACT=<p>The IL-33/ST2 axis is reported to be controversially associated with coronary artery disease (CAD). A systematic review of the association between the IL-33/ST2 axis and CAD revealed that IL-33/ST2 plays a protective role in CAD and serum sST2 and IL-33 levels are increased in patients with cardiovascular disease. Therefore, the association of IL-33/ST2 single nucleotide polymorphisms (SNPs) with CAD prevalence, prognosis, and risk factors was assessed by performing a meta-analysis. Through a literature search of relevant articles in various databases using the relevant keywords, seven studies were included in the analysis. The meta-analysis showed that the IL-33/ST2 axis was associated with increased CAD risk [pooled odds ratio (OR) = 1.17, 95% confidence interval (CI): 1.13–1.20]. Gene subgroup analysis showed a close association of <italic>IL1RL1</italic> (OR = 1.25, 95% CI: 1.20–1.30; <italic>I</italic><sup>2</sup> = 85.9%; <italic>p</italic> = 0.000) and <italic>IL1RAcP</italic> (OR = 1.42, 95% CI: 1.26–1.60; <italic>I</italic><sup>2</sup> = 27.1%; <italic>p</italic> = 0.203) with increased CAD risk. However, the association for the <italic>IL-33</italic> gene was not statistically significant. SNPs rs7044343 (T), rs10435816 (G), rs11792633 (C) in <italic>IL-33</italic> gene were associated with a protective effect in CAD. However, rs7025417 (T) in <italic>IL-33</italic>, rs11685424 (G) in <italic>IL1RL1</italic>, rs950880 (A) in <italic>sST2</italic>, and rs4624606 (A) in <italic>IL1RAcP</italic> were related to increased CAD risk. Overall, polymorphisms in IL-33/ST2 axis components were associated with increased CAD risk. These results may help identify key features of IL-33/ST2 immunobiology in CAD along with potential treatment strategies to lower disease burden.</p>